Extended Data Fig. 9: Genetic ablation of GFRAL attenuates 3A2-induced weight loss and reduction in food intake.
From: Body weight regulation via MT1-MMP-mediated cleavage of GFRAL
(a-c) Absolute body weight (a), changes in body weight (%) (b) and average daily food intake (c) of WT and Gfral-/- mice with high fat diet-induced obesity after receiving (twice a week) treatment with either 3A2 antibody or control IgG for 4 weeks (n=8). Data are reported as average ± s.e.m. two-way ANOVA for (a) (WT+3A2 & Gfral-/-+3A2: p=0.037 for 14 days; p=0.0046 for 21 days; p<0.0001 for 28 days); one-way ANOVA for (b-c).
